Serum Institute Of India (SII)

Friday, Apr 26, 2024 | Last Update : 08:57 AM IST

Serum Institute of India (SII)

SII to launch vax for kids in 6 mnths

ndia is yet to start vaccinating children below 18, who form 40 per cent of the country’s population

15 Dec 2021 1:39 AM

Apart from the Novavax vaccine that it has already exported to countries such as Indonesia, SII also makes the AstraZeneca (AZN.L) and Sputnik shots. (Representational image: AP)

Serum Institute plans to launch Novavax shot for children in six months

The Novavax shot has shown good results in trials in children aged three and older, said Adar Poonawalla

14 Dec 2021 1:48 PM

Many experts have also recommended a booster dose in India especially after the emergence of the new COVID-19 variant Omicron. (Representational image: AFP)

No recommendations for COVID-19 booster dose by SEC: Sources

Amid the emergence of the new COVID variant Omicron, the SII had sought approval to administer the booster dose of its Covishield vaccine

11 Dec 2021 12:29 PM

In this Wednesday, Oct. 7, 2020, file photo, a vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial. (Photo: AP)

India allows Serum Institute to enrol 7-11 year olds in Novavax Covid vaccine trial

Serum Institute is already conducting a trial of its COVID-19 vaccine Covovax

29 Sep 2021 11:05 AM

A health worker prepares a dose of the Covishield vaccine against the Covid-19 coronavirus at a vaccination centre in Ahmedabad. (Photo: AFP)

UK adds Covishield to approved vaccines list in updated travel advisory

The move follows widespread condemnation of the SII-manufactured vaccines not being included in a list of eligible vaccines

22 Sep 2021 2:30 PM

A health worker prepares to inoculates a man with a dose of the Covishield vaccine against the Covid-19 coronavirus. (Photo: AFP)

CII-Serum Institute to work to expand vaccination across small towns, rural areas

CII undertook a survey with responses from over 3,000 companies in 196 cities

30 Jul 2021 1:14 PM

A health worker holds a vial of the Sputnik V vaccine against COVID-19 while Charles Chaplin's movies are projected at the Lumiere movie theater, used as vaccination center, in Rosario, Santa Fe province, Argentina, on March 26, 2021. (Marcelo Manera / AFP)

Sputnik V to be produced at SII from September, says RDIF

India is the leading production hub for the production of the Sputnik vaccine

13 Jul 2021 2:12 PM

The government panel has asked the Institute to complete trials on adults first. (Photo: PTI)

Govt panel refuses SII permission to conduct Phase 2, 3 trials of Covavax on children

SII had applied to the DCGI seeking permission to conduct clinical trials of Covavax on children at 10 sites

01 Jul 2021 12:55 PM

Poonawalla on Monday said he has taken up the issues faced by Indians who have taken the Covishield jab travelling to the European Union at highest levels and hopes to resolve them soon. (PTI Photo)

Serum Institute asks govt to take up inclusion of Covishield in vaccination passport with EU

Poonawalla in his letter is learnt to have mentioned that nearly 30 crore people have already been vaccinated with Covishield in India

28 Jun 2021 3:37 PM

Employees packing boxes with COVID-19 vaccine at the packaging and dispatch department in Pune, Maharashtra. (Photo: World Health Organisation)

WHO reminds Serum Institute of its COVAX commitments amidst soaring demand in India

Earlier this month, Adar Poonawalla said it was not possible to ramp up production overnight

18 May 2021 11:18 AM

The stock of Covaxin in Delhi has finished. (Photo: AP)

Serum says will raise monthly production to 10 crore doses by August

Sources said Health Ministry and the office of DCGI had sought from both the firms their production plan for June, July, August, September

12 May 2021 10:43 PM

The Centre has purchased 11 million doses of Covishield vaccine for the ongoing inoculation drive. (Photo: AP)

Serum Institute applies for trials of another Covid-19 vaccine

The firm has already produced Covishield vaccine, co-developed by the University of Oxford and British-Swedish company AstraZeneca

31 Jan 2021 12:27 AM

1 of 1

Columns

Sunil Gatade